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ABSTRACT
Background: The aim of the present study was to
assess the effect of atopy and regular therapy for
asthma on exhaled nitric oxide (eNO).
Methods: Exhaled NO was measured using a chemi-
luminescence analyzer during slow expiration in 83
children, aged 5–7 years, after hospitalization for
wheezing in infancy. The mean (±SD) age of the sub-
jects was 7.2 ± 0.7 years, 28% were girls and 42%
were atopic. A total of 31 children (37%) had asthma
with regular medication: 20 were taking cromones,
and 11 were taking inhaled steroids.
Results: In the asthma group, the median concentra-
tion of eNO was 14.9 p.p.b. (range 3.5–56.1 p.p.b.)
in atopics and 7.3 p.p.b. (range 5.1–15.6 p.p.b.) in
non-atopics (P < 0.01). The levels for atopic children
on cromones tended to be higher than for those on
inhaled steroids; however, the difference did not reach
statistical significance.
Conclusion: We conclude that eNO concentrations
associate significantly with atopic asthma.
Key words: asthma, atopy, children, cromone,
exhaled nitric oxide, inhaled steroid, skin prick test.
INTRODUCTION
Exhaled nitric oxide (eNO) has been reported to be raised
in children with asthma.1–6 The probable explanation for
this is an ongoing inflammation of the lower airways.4,7
However, atopic and infectious manifestations of both
upper and lower airways may also elevate eNO concen-
trations5,8,9 and inhaled glucocorticosteroids,2,10 as well
systemic ones, may reduce it.3,11 The measurement of
eNO has been suggested to be a useful, non-invasive,
easy-to-perform method to monitor asthmatic inflam-
mation.3,4,11
Many studies have evaluated the role of eNO in moni-
toring the effectiveness of steroid medication in children
with asthma but, in most studies, the number of patients
has been rather low. The studies have offered evidence
that inhaled steroids decrease eNO concentrations.1,3,11–14
To our knowledge, only one report has suggested that
regular cromone therapy reduces levels of eNO in chil-
dren with asthma.15 According to the international guide-
lines, cromones are recommended as first-line drugs for
mild-to-moderate asthma in school-aged children.16
The aims of the present study were to examine eNO
concentrations in children who had been treated in hos-
pital for wheezing in early childhood, followed from
infancy to school age, and to assess how atopy and
regular therapy for asthma influence eNO.
METHODS
Study design
A total of 95 children who had been treated in hospital
for early childhood wheezing in over the period
1992–9317 attended a follow-up visit in the Department
of Paediatrics, Kuopio University Hospital, eastern
Finland, in March 1999. At the study visit, eNO was
measured and skin prick tests (SPT) were performed. The
parents were advised not to give sympathomimetics to
their children for 12 h preceding the eNO measurement.
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In addition, they were told that topical corticosteroids for
the skin had to be avoided for 2 days, oral short-acting
antihistamines had to be avoided for 3 days and oral
long-acting antihistamines had to be avoided for 5 days
prior to the investigation. The use of regular medication
for asthma (i.e. inhaled steroids or cromones) was not
restricted. Children who had had symptoms suggestive of
respiratory infection during the preceding 2 weeks of the
measurement were not allowed to participate in the study.
Symptoms suggestive of allergic rhinitis, if present during
the study, were recorded.
Detailed data of ongoing regular therapy for asthma
were registered. The doses we usually prescribe for main-
tenance therapy for steady state asthma are 100–200 µg
twice daily for inhaled steroids (budesonide and beclo-
methasone), 20 mg three times daily for cromolyn
sodium and 6 mg twice daily for nedocromil. Among
the 95 children studied, 12 used budesonide, two 
used beclomethasone, 15 used cromolyn sodium and
seven used nedocromil. Budesonide was delivered by
Turbuhaler® (AstraZeneca, Masala, Finland), beclo-
methasone by Easyhaler® (Orion, Espoo, Finland),
cromolyn sodium by Eclipse® (Rhône-Poulenc Rorer,
Helsinki, Finland), and nedocromil as an aerosol prepa-
ration by Syncroner® (Rhône-Poulenc Rorer).
Definition of asthma
Current asthma was considered to be present if either of
the following criteria were fulfillled: (i) the patient was on
continuous maintenance medication for asthma and had
a history of at least three physician-confirmed wheezing
episodes; or (ii) the patient had had a physician-
confirmed wheezing episode during the preceding 
12 months and had a history of at least two additional
physician-confirmed wheezing episodes.16 During the
follow-up visit, asthma was divided into five categories on
the basis of recent symptoms18 assessed clinically by one
of the authors (MK). According to our guidelines, children
with mild-to-moderate asthma are treated with cromones
and those with severe symptoms or those not responding
to cromone therapy are treated with inhaled steroids.19
Pulmonary function testing
The baseline pulmonary function was examined by flow-
volume spirometry (Medikro, Kuopio, Finland), and
forced expiratory volume in 1 s (FEV1) was the parameter
used to assess the degree of obstruction. The result of at
least 75% of that of predicted was regarded as a
normal.19 First, the children were carefully instructed on
how to perform the test. Thereafter, measurements were
repeated at least three times and accepted if the FEV1
variation was less than 5% and the printed graphic curves
were appropriate and equal in shape. The highest FEV1
value was selected.
Measurement of eNO
The eNO concentrations were measured using a chemi-
luminescence analyzer (NOA 280; Sievers Instruments,
Boulder, CO, USA).20 Subjects were asked to avoid phys-
ical exercise for at least 15 min prior to the measurement.
During measurement, subjects were seated while slowly
exhaling from total lung capacity for a 20–30 s period
against a fixed expiratory resistance (20 mmHg), by
closing the velum of the soft palate, to eliminate contam-
ination with nasal NO. A biofeedback exhalation flow
display provided visual guidance to help the subject
maintain their exhalation flow at the desired level of 
50 mL/s. Exhaled air was led through a norebreathing
valve into a Teflon tubing system connected to the 
analyzer. Recordings were performed by a single-breath
program (Sievers Restricted Exhaled Breath Program
2.01; Sievers Instruments). Two successive exhaled samples
were obtained from all subjects.4,21 The relative standard
deviation between the samples was expected to be below
10%, with results being expressed as mean values, using
a unit of parts per billion (p.p.b). The measurements were
performed in the same laboratory under constant condi-
tions under the supervision of one of the authors (KK) and
were stored digitally on the computer. Readings from the
stored data were made by another investigator (MP) who
was unaware of either clinical data or the results of the
SPT of the study subjects. The chemiluminescence ana-
lyzer was calibrated daily using a zero air and a certified
concentration of NO.
Skin prick testing
Skin prick tests were performed for all children. The aller-
gens (ALK skin prick test extracts; ALK Laboratories,
Copenhagen, Denmark) tested were the outdoor aller-
gens birch, common alder, timothy grass, meadow grass
and mugwort pollens and spores of Cladosporium
herbarum. The indoor allergens tested were cat and dog
epithelial danders and home dust mites Dermato-
phagoides pteronyssimus and Dermatophagoides farinae.
The concentration of the non-standardized allergen
extract, C. herbarum spore, was 1 : 20 weight/volume.
Other allergen extracts were standardized, the concen-
trations being 10 histamine equivalent points. Histamine
hydrochloride (10 mg/mL) was used as a positive control
and 50% glycerol was used as a negative control. Wheals
with a median diameter of at least 3 mm were regarded
as positive22 and no reactions were allowed in negative
controls. A child was defined to be atopic if there was at
least one positive result in the SPT.
Patients
The eNO results of nine of 95 children were excluded
from analysis because of acute respiratory infection in
four cases, poor repeatability of the successive measure-
ments in three cases and insufficient cooperation in two
cases. Data of three non-treated children with asthma are
presented separately and are not included in the statisti-
cal analyses. The remaining 83 children, with a mean
(±SD) age of 7.2 ± 0.7 years, were included in the
analyses; 28% were girls, 42% were atopic and 37% had
asthma. Only two children had symptoms suggestive of
allergic rhinitis at the time of the measurement. All but the
three children with asthma were taking regular medica-
tion for asthma: cromones in 20 cases (59%) and inhaled
steroids in 11 cases (32%).
Ethics
The study design was approved by the Research Ethics
Committee of Kuopio University Hospital. Informed
written consent was obtained from the parents of the
children.
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Fig. 1 Levels of exhaled nitric oxide (NO) for 31 children with asthma and for 52 children with no asthma, presented in relation to
atopy. The 31 children with asthma were on regular medication. The line in each box is the median; box limits represent the 25th and
75th percentiles; the whiskers extend to the 5th and 95th percentiles. Values above the 95th percentile are plotted separately. The
two atopic, non-asthmatic outliers are excluded from the statistical analyses (see text).
Statistics
Data were analyzed using SPSS/PC+9.0 software (SPSS,
Chicago, IL, USA). The Kolmogorov–Smirnov test was
applied to assess the normality of the distributions of contin-
uous variables. Because the data for eNO did not follow a
normal distribution, not even after logarithmic transforma-
tion, a non-parametric Mann–Whitney U-test was used in
comparisons between groups. Fisher’s exact test was used
for 2 × 2 contingency tables. A general linear model, apply-
ing natural logarithmic transformed data, was used to
assess both the main and interaction effects of confounding
factors on the levels of eNO. Skin prick test reactivity,
asthma and sex were the variables included in the model.
RESULTS
The mean (±SD) age of the 83 study subjects was 7.2 ±
0.7 years, 60 (72%) were male and 31 (37%) had
medicated asthma. The baseline FEV1 was normal for
every child included in the analysis. The children were
classified into four categories on the basis of the presence
of atopy and asthma (Fig. 1). As seen in Fig. 1, there
were two atopic, non-asthmatic children with exception-
ally high eNO values over 45 p.p.b. These children were
regarded as outliers23 and they were excluded from
further analyses. In fact, they had had subjective symp-
toms suggestive for asthma (e.g. prolonged cough), but
they did not fulfill the objective criteria for asthma. The
eNO values were higher among the atopic than non-
atopic children. The difference was significant in the
asthma (P < 0.01) but not in the non-asthma group. The
distribution of eNO values was especially wide and
skewed to the right if both asthma and atopy were
present.
The effects of atopy, asthma and sex on eNO were
studied by including them in the general linear model.
The children were rather homogeneous in age, which
was not considered a confounding factor and was not
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Fig. 2 Levels of exhaled nitric oxide (NO) for 20 children with asthma treated by cromones and for 11 children treated by inhaled
steroids, presented in relation to atopy. The line in each box is the median; box limits represent the 25th and 75th percentiles; the
whiskers extend to the 5th and 95th percentile.
included in the model. Atopy, defined as one or more
positive reactions in the SPT, was the only factor that had
a significant association (P < 0.01). No interactions
between atopy, asthma and sex were found. Among the
children with asthma on regular medication, 23 of 31
had mild symptoms. There were only three children
with no symptoms and five had moderate or severe
symptoms; these figures were too small for any statisti-
cal calculations.
The effects of treatment strategy on eNO were ana-
lyzed separately for the asthma group (Fig. 2). Among the
20 children on cromones, eNO values were significantly
higher for atopic than non-atopic children (P < 0.05). 
A similar trend, although not statistically significant, was
seen among children on inhaled steroids. However, eNO
did not differ between children on cromones and those
on inhaled steroids. The result was the same whether or
not it was adjusted for atopy.
The 95th percentiles for eNO concentrations were cal-
culated for children with no asthma, separately for atopic
and non-atopic children. Among the non-atopic children,
the limit was 16.8 p.p.b. and it was exceeded in 0 of 11
cases if asthma was present and in five of 37 cases (14%)
if it was not (NS). Among the atopic children, the respec-
tive limit was 22.9 p.p.b. and it was exceeded in seven of
20 cases (35%) if asthma was present and in two of 15
cases (13%) if it was not (NS).
The three children with non-treated asthma were boys,
aged 5.9–7.1 years. Two had positive SPT reactions to
indoor allergens and none reacted positively to outdoor
allergens. The eNO values were 46.5 and 7.0 p.p.b. for
the two atopic children and 11.5 p.p.b. for the non-
atopic child.
DISCUSSION
In agreement with earlier reports, high eNO values were
significantly associated with atopy.5,8 We defined atopy
on the basis of skin test results. This is an objective way to
screen atopics from non-atopics, especially if anti-inflam-
matory medication is used. Elevated levels of eNO have
also been reported in children with non-treated asthma.6
When atopy has been taken into account, high eNO
levels have been reported among children with atopic
asthma, but not among those with non-atopic asthma.5
In the present study, all but three children with asthma
were on regular medication and asthma alone was not
significantly associated with high eNO. This may reflect
the efficacy of the regular therapy. In contrast, the 95th
percentile for atopic children with asthma was exceeded
by one-third of cases.
The expression of an enzyme responsible for the pro-
duction of NO, inducible NO synthase (iNOS), is inhib-
ited by glucocorticosteroids.24 Byrnes et al. found that
eNO was higher among children with asthma on bron-
chodilator therapy than among those on regular inhaled
steroids. Moreover, it has been shown that eNO is
reduced after commencement of inhaled steroid treat-
ment.2,10,12,14 Interestingly, in a Swedish study, eNO
remained higher than normal in atopic children even
though their asthma was treated with inhaled steroids
and was considered as stable.4 To our knowledge, only
one report has suggested that cromones also reduce
eNO in children.15 A limitation of that study was the very
small number of children on cromones (only five sub-
jects). We followed 83 children from infancy to school
age and 20 of them were on cromones at the follow-up
visit. Our results suggest that cromones may not reduce
eNO as effectively as inhaled steroids. However, no 
statistical difference in eNO was found between these
two medication groups, in all probability owing to the
small number of steroid-treated subjects.
Most children from the age of 7 years onwards are
able to achieve and maintain a steady flow during eNO
measurements.3,8 Our experiences are in accordance
with these findings: after careful instruction, reliable mea-
surement of eNO failed in only 5% of children.
There are three strengths to our study. First, the cohort
was rather homogeneous: the average age variation of
the subjects was less than 1 year. Second, we have fol-
lowed up the children from infancy, so their asthma
diagnoses are based on long-term prospective follow
up. Third, the study was performed outside the pollen
seasons, which are known to affect results.25 However,
two atopic children on cromones had symptoms sug-
gestive of both asthma and allergic rhinitis at the time of
the eNO measurement and both of these had elevated
eNO levels. In addition, to maximize the objectivity of
the results, different physicians were responsible for pre-
scription and follow up of regular therapy for asthma,
for clinical definition of current asthma, for perfor-
mance of the tests and for the interpretation of the
results.
Only three children with current asthma had no regular
medication, so statistical analyses were not possible for
them. There are three other minor shortcomings in the
present study. First, because the cohort consisted of chil-
dren admitted to hospital for wheezing in early childhood,
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all subjects had wheezed at least once, so there was no
optimal control group. Second, there were many sub-
groups in relation to asthma and atopy in the cohort,
leading to small numbers of cases and to low powers in
statistical analyses. Third, the distributions of eNO levels
were skewed. The majority of values were low, allowing
patient-specific evaluation of the high values.
In conclusion, eNO concentrations associate with
atopic asthma. The results were rather similar in children
with regular therapy for asthma and in those with no
asthma, reflecting the effectiveness of anti-inflammatory
therapy.
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